Pharmacogenetics: potential for individualized drug therapy through genetics

被引:67
作者
Johnson, JA
机构
[1] Univ Florida, Dept Pharm Practice, Gainesville, FL 32610 USA
[2] Univ Florida, Dept Pharmaceut, Gainesville, FL 32610 USA
[3] Univ Florida, Dept Med, Gainesville, FL 32610 USA
关键词
D O I
10.1016/j.tig.2003.09.008
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Pharmacogenetics blends important components of the disciplines of genetics and pharmacology, and aims to describe the influence of inheritance on variable drug response. This review provides an overview of the history and current status of pharmacogenetics. The role of genetics in variable drug response is now firmly established. To apply this information to the clinical setting, more sophisticated methods, such as a multiple candidate gene approach, or genomic approaches, are likely to be needed. Most drugs will require additional research if their use is be guided by a patient's genetic make-up. However, it seems that the potential for pharmacogenetics to improve the clinical outcomes of numerous drug therapies will be realized, and will represent an important biomedical advance in the post-genomics era.
引用
收藏
页码:660 / 666
页数:7
相关论文
共 52 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]   Pharmacogenetic prediction of clozapine response [J].
Arranz, MJ ;
Munro, J ;
Birkett, J ;
Bolonna, A ;
Mancama, D ;
Sodhi, M ;
Lesch, KP ;
Meyer, JFW ;
Sham, P ;
Collier, DA ;
Murray, RM ;
Kerwin, RW .
LANCET, 2000, 355 (9215) :1615-1616
[3]   Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine [J].
Black, AJ ;
McLeod, HL ;
Capell, HA ;
Powrie, RH ;
Matowe, LK ;
Pritchard, SC ;
Collie-Duguid, ESR ;
Reid, DM .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (09) :716-718
[4]   Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects [J].
Bloemenkamp, KWM ;
Rosendaal, FR ;
Helmerhorst, FM ;
Vandenbroucke, JP .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (01) :49-52
[5]   The impact of the CYP2D6 polymorphism on haloperidol pharmacoldnetics and on the outcome of haloperidol treatment [J].
Brockmöller, J ;
Kirchheiner, J ;
Schmider, J ;
Walter, S ;
Sachse, C ;
Müller-Oerlinghausen, B ;
Roots, I .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (04) :438-452
[6]   Ethical, legal, and social implications of genomic medicine [J].
Clayton, EW .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (06) :562-569
[7]   A vision for the future of genomics research [J].
Collins, FS ;
Green, ED ;
Guttmacher, AE ;
Guyer, MS .
NATURE, 2003, 422 (6934) :835-847
[8]   Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension [J].
Cusi, D ;
Barlassina, C ;
Azzani, T ;
Casari, G ;
Citterio, L ;
Devoto, M ;
Glorioso, N ;
Lanzani, C ;
Manunta, P ;
Righetti, M ;
Rivera, R ;
Stella, P ;
Troffa, C ;
Zagato, L ;
Bianchi, G .
LANCET, 1997, 349 (9062) :1353-1357
[9]   Pharmacogenetics of oral anticoagulants [J].
Daly, AK ;
King, BP .
PHARMACOGENETICS, 2003, 13 (05) :247-252
[10]  
Eichhammer P, 2000, AM J MED GENET, V96, P187, DOI 10.1002/(SICI)1096-8628(20000403)96:2<187::AID-AJMG13>3.0.CO